Antech expands its molecular diagnostics offerings

Cancer diagnostics, from digital cytology and advanced imaging to new molecular tests, help veterinarians fight the leading cause of canine death

Antech’s cancer diagnostics portfolio now includes SearchLight DNA from Vidium Animal Health and OncoK9 from PetDx. These new tests add to Antech’s canine cancer diagnostics portfolio which covers several essential diagnostic modalities, including ultrasound, digital cytology and molecular medicine.

SearchLight DNA is a genomic test that analyzes DNA from a dog’s tumor cells, looking for mutations in 120 relevant cancer genes, to identify mutations that aid in cancer diagnosis and prognosis and help guide treatment decisions.

OncoK9 is a “liquid biopsy” multi-cancer early detection blood test that helps veterinarians detect 30 different types of cancer, including 8 of the most common cancers in dogs. OncoK9 has been clinically validated in the CANDiD (CANcer Detection in Dogs) study using samples prospectively collected from more than 1,000 customer-owned dogs at more than 40 clinical sites, according to a statement from Antech. .1

“A diagnosis of cancer can be devastating to a pet owner,” said Sue Ettinger, DVM, DACVIM (Oncology). “Accurate diagnosis and care can be costly and complex. Reading the genomic material from tumour, molecular diagnostics gives us an unprecedented level of transparency into the nature of the cancer, allowing us to diagnose it earlier and develop a highly personalized treatment plan.

According to a press release from Antech, the ability of these advanced diagnostic tests to analyze the DNA of tumor cells provides specific information about mutations that cause cancer to grow and spread and can help veterinarians identify cancer. often when it is most treatable. Molecular diagnostics can also help veterinarians understand the origin and behavior of cancer, which can guide the optimal approach to treatment.1

“Cancer has been and continues to be a frustrating disease for pet owners and veterinarians to diagnose and treat,” said Cathleen Meeks, MS, DVM, DACVIM, Vice President of Medical Operations at Antech. “Antech is dedicated to the continuous advancement of our diagnostic capabilities in oncology to help provide innovative ways to diagnose this disease over traditional methods. This will allow us to improve the quality of care by diagnosing these diseases earlier than in the past and avoiding delays in starting treatment.

“Cancer has claimed the lives of too many beloved dogs, too soon and for too long,” said Lonnie Shoff, president of Antech. “I believe we are at the precipice of a new era in the treatment of canine cancer; one that offers new hope to veterinarians and pet owners. That’s why we’re expanding our portfolio of canine cancer diagnostics. From molecular diagnostics, to pathology expertise, to being veterinary medicine’s most trusted provider of digital x-rays, ultrasound, laser therapy, mobile computed tomography, assistive imaging and PACS, we will continue to provide the most advanced diagnostic tools to veterinarians to effectively combat this. dreadful disease. Offering the latest molecular diagnostics for cancer detection and personalized treatment is simply the right thing to do. We will continue to spare no effort as we strive to help veterinary teams tackle this leading cause of canine death.


Antech expands molecular diagnostics offerings in veterinary medicine’s most comprehensive portfolio of diagnostics for canine cancer. Antech Diagnostics. September 12, 2022. Accessed September 15, 2022. canine-cancer-301621988.html

Comments are closed.